I have never bought high but did buy too early, but again that goes back as far as Amadeus in the multi port.
I bought as low as nine cents pre-split and everything under a dollar except once at $1.20 pre-split. I bought at $.68 again last year, the only part of my investment in the green. I never bought high but the reverse split and crashing of PPS since due to perpetual lying about timelines followed by multiple year delays for FDA and robot completion killed the investment. I’ve never sold.
This is literally the worst managed company over multiple teams I’ve ever seen; both fiscally and with product development. They have no clue what the market actually is looking for.
A standalone SP is not the future, even with three arms. It can’t do complex multi quadrant surgery. Therefore, it will never be able to be the only robot in a hospital. On top of that, MDT proved what I have been saying for years. nobody wants a standalone SP robot that doesn’t work off of the same software as their MP robot and surgeon console.
And the biggest specialty that Titan was targeting was Gyn. Look on the AAGL website which is the American Association of Gynecologic Laparoscopic Surgeons. They recommend transvaginal hysterectomies and other procedures over laparoscopic. Titan missed the boat taking 10 years to get the market on that one.
So, no money to get the FDA. A mock up third arm PR’d as the future that intuitive has had for seven years, and MDT tied up their ability to license any technology. What am I missing??
BelizeMe
News 
Market Data 
Discover 
